PharmEnable Secures $7.5 Million for Drug Discovery Innovations
PharmEnable, a drug discovery company based in Cambridge, UK, has successfully secured a substantial amount of funding to propel its innovative research and development efforts. The company closed a Pre-Series A funding round, raising $7.5 million, a significant boost to its mission of exploring chemical novelty, diversity, and complexity in drug discovery. This funding round was led by MP Healthcare Venture Management, which is the venture arm of Mitsubishi Tanabe Pharma Group. Additional contributions came from a range of existing investors, including prestigious organizations such as Cambridge Enterprise, the commercialization arm of the University of Cambridge, along with University of Cambridge Enterprise Fund VIII, managed by Parkwalk Advisors, Heyford Trust, o2h Ventures, Martlet Capital, Arrowfield Capital, Wren Capital, and notable angel investors with expertise in life sciences, including Jonathan Milner.
With this new infusion of capital, PharmEnable is poised to accelerate its ongoing research initiatives and broaden its portfolio of wholly owned and co-discovery projects that target critical areas within oncology and neurology.
The company’s pioneering approach leverages proprietary technology to discover targeted therapies that seek to mirror the specificity typically associated with biologics while enhancing efficacy and distribution through tailor-made oral small molecules. These custom-designed molecules are also more scalable and easier to manufacture, addressing a significant gap in the pharmaceutical landscape. The integration of advanced medicinal chemistry techniques with artificial intelligence technology further empowers PharmEnable to navigate and unlock challenging biological targets, broadening the horizons of unexplored chemical space in the drug discovery process.
Moreover, PharmEnable’s strategic initiatives include a diverse pipeline of wholly owned oncology programs, which are geared towards addressing pivotal challenges such as tumor penetration and the development of mechanisms to overcome resistance in cancer treatment. The company is also actively engaged in co-discovery collaborations with multiple pharmaceutical and biotech firms, including a significant partnership with Sosei Heptares aimed at identifying novel drug candidates for neurological diseases. The focus on designing complex small molecules that offer enhanced selectivity and well-balanced therapeutic properties positions PharmEnable at the forefront of innovation in drug discovery, addressing critical needs in modern medicine.
They've invested in PharmEnable
Get to know these Biotech investors
| Investors | Investment Focus | Startup Investments | Round Size | Connect |
|---|---|---|---|---|
 MP Healthcare Venture Management( ) Boston, US  | ||||
 | ||||
 University of Cambridge Enterprise Fund VIII( ) Cambridge  | ||||
 Parkwalk Advisors( ) Parkwalk is a leading UK growth fund manager focused on investing in world-chang... London | ||||
 o2h Ventures( ) | ||||
 Martlet Capital( ) Martlet Capital is a pre-seed and seed stage investor based in Cambridge, focusi... Birmingham | ||||
 Arrowfield Capital( ) | ||||
 Wren Capital( ) Wren is an angel investor founded in 2011, focusing on sectors such as science, ... London | ||||
| All investors | All investor sectors | All funded startups | All funding rounds |
Click here for a full list of 7,589+ startup investors in the UK